Pyxis Oncology (NASDAQ:PYXS) Announces Earnings Results

Pyxis Oncology (NASDAQ:PYXS) posted its quarterly earnings data on Thursday. The company reported ($0.24) EPS for the quarter, topping analysts’ consensus estimates of ($0.27) by $0.03, FiscalAI reports.

Pyxis Oncology Trading Down 3.0%

Shares of NASDAQ:PYXS traded down $0.05 during trading on Thursday, hitting $1.61. 1,149,574 shares of the company’s stock were exchanged, compared to its average volume of 834,470. Pyxis Oncology has a 1-year low of $1.03 and a 1-year high of $5.55. The firm has a 50-day moving average price of $2.54 and a two-hundred day moving average price of $2.16. The firm has a market cap of $134.29 million, a P/E ratio of -1.14 and a beta of 1.41.

Analysts Set New Price Targets

A number of analysts have recently weighed in on the company. HC Wainwright raised their target price on Pyxis Oncology from $7.00 to $8.00 and gave the company a “buy” rating in a research note on Thursday, September 10th. Stifel Nicolaus set a $5.00 price target on shares of Pyxis Oncology in a research report on Thursday. Wedbush upped their price target on shares of Pyxis Oncology from $6.00 to $8.00 and gave the stock an “outperform” rating in a research report on Thursday, September 10th. Wells Fargo & Company increased their price objective on shares of Pyxis Oncology from $12.00 to $19.00 and gave the stock an “overweight” rating in a report on Wednesday, September 9th. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of Pyxis Oncology in a research report on Friday, September 25th. Seven research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $8.57.

About Pyxis Oncology

Pyxis Oncology, Inc is a clinical-stage biotechnology company focused on developing antibody-based therapies for the treatment of cancer. The company aims to address limitations of existing cancer treatments by designing therapeutics intended to selectively target tumors and activate the immune system while minimizing effects on healthy tissue.

Pyxis Oncology’s pipeline includes antibody-drug conjugates and immunotherapies designed to act on targets in the tumor microenvironment. Its lead programs have included PYX-201, an antibody-drug conjugate intended to deliver a cytotoxic payload to tumors expressing the fibronectin extra domain-B target, and other investigational antibody-based programs directed at immune-suppressive pathways.